New flu drug stops virus in its tracks

February 21, 2013
This figure shows the life cycle of the flu virus and how the new flu drug agent prevents the virus from spreading from cell to cell by irreversibly inhibiting the action of the neuraminidase like a broken key left in a lock. Credit: Tom Wennekes, UBC

A new class of influenza drug has been shown effective against drug-resistant strains of the flu virus, according to a study led by University of British Columbia researchers.

Published online today in the journal , the study details the development of a new drug candidate that prevents the from spreading from one cell to the next. The drug is shown to successfully treat mice with lethal strains of the flu virus.

In order to spread in the body, the flu virus (blue) first uses a protein, called hemagglutinin, to bind to the receptors (green) on a healthy cell (red).

In order to spread in the body, the flu virus first uses a protein, called hemagglutinin, to bind to the healthy cell's receptors. Once it has inserted its RNA and replicated, the virus uses an enzyme, called neuraminidase, to sever the connection and move on to the next healthy cell.

"Our drug agent uses the same approach as current flu treatments – by preventing neuraminidase from cutting its ties with the infected cell," says UBC Chemistry Prof. Steve Withers, the study's senior author. "But our agent latches onto this enzyme like a broken key, stuck in a lock, rendering it useless."

The estimates that influenza affects three to five million people globally each year, causing 250,000 to 500,000 deaths. In some pandemic years, the figure rose to millions.

The video will load shortly

"One of the major challenges of the current flu treatments is that new strains of the flu virus are becoming resistant, leaving us vulnerable to the next pandemic," says Withers, whose team includes researchers from Canada, the UK, and Australia.

"By taking advantage of the virus's own 'molecular machinery' to attach itself," Withers adds. "The new drug could remain effective longer, since resistant cannot arise without destroying their own mechanism for infection."

Explore further: FDA approves first 4-in-1 flu vaccine

More information: "Mechanism-Based Covalent Neuraminidase Inhibitors with Broad Spectrum Influenza Antiviral Activity," by J.-H; Kim et al, Science, 2013.

Related Stories

FDA approves first 4-in-1 flu vaccine

February 29, 2012

Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.

Searchers map the global spread of drug-resistant influenza

September 14, 2011

In the new movie "Contagion," fictional health experts scramble to get ahead of a flu-like pandemic as a drug-resistant virus quickly spreads, killing millions of people within days after they contract the illness.

Recommended for you

Formaldehyde damages proteins, not just DNA

September 29, 2016

The capacity of formaldehyde, a chemical frequently used in manufactured goods such as automotive parts and wood products, to damage DNA, interfere with cell replication and cause cancer inspired new federal regulations this ...

Synthetic 3D-printed material helps bones regrow

September 28, 2016

A cheap and easy to make synthetic bone material has been shown to stimulate new bone growth when implanted in the spines of rats and a monkey's skull, researchers said Wednesday.

Epigenetic clock predicts life expectancy

September 28, 2016

UCLA geneticist Steve Horvath led a team of 65 scientists in seven countries to record age-related changes to human DNA, calculate biological age and estimate a person's lifespan. A higher biological age—regardless of chronological ...

Engineered blood vessels grow in lambs

September 27, 2016

In a hopeful development for children born with congenital heart defects, scientists said Tuesday they had built artificial blood vessels which grew unaided when implanted into lambs, right into adulthood.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.